{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:01:17Z","timestamp":1777536077862,"version":"3.51.4"},"reference-count":36,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,3,7]],"date-time":"2014-03-07T00:00:00Z","timestamp":1394150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2014,4]]},"abstract":"<jats:p>Gemtuzumab ozogamicin (fGO), a humanized anti\u2010CD33 monoclonal antibody linked to calicheamicin in combination with intensive chemotherapy gives high response rates in adult acute myeloid leukemia (AML) patients in relapse. However, reduced intensity chemotherapy in combination with fractionated GO has not been tested in aged relapsing patients. Patients from our institution with CD33+ AML aged 55 years or more in first late relapse (\u22656 months) were proposed participation in a GO compassionate use program. Induction therapy consisted in fractionated GO (fGO; 3 mg\/m<jats:sup>2<\/jats:sup>, days 1, 4, 7) with standard\u2010dose cytarabine (200 mg\/m<jats:sup>2<\/jats:sup>\/day, 7 days). Patients were consolidated with two courses of GO and intermediate dose cytarabine. Twenty\u2010four patients (median age 68 years) received fGO with cytarabine. Median follow\u2010up was 42 months. The response rate was 75%, including complete remission (CR) in 16 patients and CR with incomplete platelet recovery (CRp) in two patients. Two\u2010year overall survival (OS) was 51% (95% CI: 28\u201369) and 2 years relapse\u2010free survival (RFS) was 51% (95%CI: 25\u201372). Duration of second CR (CR2) was longer than first CR (CR1) in 9 out of 18 patients. Minimal residual disease (MRD) was negative in evaluable patients in CR2, particularly in <jats:italic>NPM1<\/jats:italic> mutated cases. Toxicity was in line with that of the same fractionated single agent GO schedule. Fractionated GO with low intensity chemotherapy produced high response rates and prolonged CR2 in aged AML patients in first late relapse. Am. J. Hematol. 89:399\u2013403, 2014. \u00a9 2013 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23653","type":"journal-article","created":{"date-parts":[[2013,12,21]],"date-time":"2013-12-21T09:08:37Z","timestamp":1387616917000},"page":"399-403","source":"Crossref","is-referenced-by-count":22,"title":["Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse"],"prefix":"10.1002","volume":"89","author":[{"given":"Sylvain","family":"Pilorge","sequence":"first","affiliation":[{"name":"Service d'H\u00e9matologie et d'Oncologie H\u00f4pital Andr\u00e9 Mignot Le Chesnay France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Rigaudeau","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie et d'Oncologie H\u00f4pital Andr\u00e9 Mignot Le Chesnay France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Rabian","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie et d'Oncologie H\u00f4pital Andr\u00e9 Mignot Le Chesnay France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mentine","family":"Sarkozy","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie et d'Oncologie H\u00f4pital Andr\u00e9 Mignot Le Chesnay France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne L.","family":"Taksin","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie et d'Oncologie H\u00f4pital Andr\u00e9 Mignot Le Chesnay France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Farhat","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie et d'Oncologie H\u00f4pital Andr\u00e9 Mignot Le Chesnay France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fathia","family":"Merabet","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie et d'Oncologie H\u00f4pital Andr\u00e9 Mignot Le Chesnay France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Ghez","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie et d'Oncologie H\u00f4pital Andr\u00e9 Mignot Le Chesnay France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Raggueneau","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Biologie M\u00e9dicale H\u00f4pital Andr\u00e9 Mignot Le Chesnay France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Terr\u00e9","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Biologie M\u00e9dicale H\u00f4pital Andr\u00e9 Mignot Le Chesnay France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Garcia","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Biologie M\u00e9dicale H\u00f4pital Andr\u00e9 Mignot Le Chesnay France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline","family":"Renneville","sequence":"additional","affiliation":[{"name":"Laboratoire d'H\u00e9matologie, Centre de Biologie\u2010Pathologie CHRU Lille, Universit\u00e9 de Lille Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Preudhomme","sequence":"additional","affiliation":[{"name":"Laboratoire d'H\u00e9matologie, Centre de Biologie\u2010Pathologie CHRU Lille, Universit\u00e9 de Lille Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Castaigne","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie et d'Oncologie H\u00f4pital Andr\u00e9 Mignot Le Chesnay France"},{"name":"Universit\u00e9 Versailles Saint\u2010Quentin\u2010en\u2010Yvelines Versailles France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Rousselot","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie et d'Oncologie H\u00f4pital Andr\u00e9 Mignot Le Chesnay France"},{"name":"Universit\u00e9 Versailles Saint\u2010Quentin\u2010en\u2010Yvelines Versailles France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,3,7]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401853"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000006529"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.027516"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.4245"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.027"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V67.4.1048.1048"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.10.3197"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21326"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.9764"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.07.017"},{"key":"e_1_2_7_12_1","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2141.2008.07370.x","article-title":"Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia","volume":"43","author":"Brethon B","year":"2008","journal-title":"Br J Haematol"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-007-0272-z"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2004.01.009"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-002-0546-z"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(03)00021-3"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(03)00022-5"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-002-0539-y"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.13.3244"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7930"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm451"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404434"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22201"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60485-1"},{"key":"e_1_2_7_25_1","first-page":"1","volume-title":"Supplement to an International System for Human Cytogenetic Nomenclature","author":"Mittelman F","year":"1991"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8500"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403135"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404149"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.4865"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.112"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-235358"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr346"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23498"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.214"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-363291"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23128"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23653","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23653","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T15:33:08Z","timestamp":1696606388000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,7]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.1002\/ajh.23653"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23653","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,7]]}}}